Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A. Sawaki A, et al. Among authors: kuriki h. Gastric Cancer. 2018 May;21(3):429-438. doi: 10.1007/s10120-017-0773-y. Epub 2017 Oct 20. Gastric Cancer. 2018. PMID: 29058097 Free PMC article. Clinical Trial.
Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
Fuse N, Bando H, Chin K, Ito S, Yoshikawa T, Tsuburaya A, Terashima M, Kawashima Y, Fukunaga T, Gotoh M, Emi Y, Yoshida K, Oki E, Takahashi S, Kuriki H, Sato K, Sasako M. Fuse N, et al. Among authors: kuriki h. Gastric Cancer. 2017 Mar;20(2):332-340. doi: 10.1007/s10120-016-0606-4. Epub 2016 Mar 8. Gastric Cancer. 2017. PMID: 26956689 Free PMC article. Clinical Trial.
Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.
Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A, Kobayashi T, Nakano K, Tomomatsu J, Ito Y, Tanaka J, Kuriki H, Gu Z, Takahashi S. Tamura K, et al. Among authors: kuriki h. Cancer Sci. 2018 May;109(5):1592-1601. doi: 10.1111/cas.13561. Epub 2018 Mar 31. Cancer Sci. 2018. PMID: 29500843 Free PMC article. Clinical Trial.
Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K. Ohmachi K, et al. Among authors: kuriki h. Int J Hematol. 2018 Nov;108(5):499-509. doi: 10.1007/s12185-018-2497-0. Epub 2018 Jul 19. Int J Hematol. 2018. PMID: 30027429 Clinical Trial.
Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study.
Ohmachi K, Ando K, Kinoshita T, Kumagai K, Hatake K, Ishikawa T, Teshima T, Kato K, Izutsu K, Ueda E, Nakai K, Kuriki H, Tobinai K. Ohmachi K, et al. Among authors: kuriki h. Jpn J Clin Oncol. 2018 Aug 1;48(8):736-742. doi: 10.1093/jjco/hyy087. Jpn J Clin Oncol. 2018. PMID: 30060000 Free PMC article. Clinical Trial.
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Kuriki H, Shimada T, Tanaka T, Takeuchi K, Nishio M. Tamura T, et al. Among authors: kuriki h. J Clin Oncol. 2017 May 10;35(14):1515-1521. doi: 10.1200/JCO.2016.70.5749. Epub 2017 Mar 15. J Clin Oncol. 2017. PMID: 28296581 Free PMC article. Clinical Trial.
Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].
Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T. Nishio M, et al. Among authors: kuriki h. Lung Cancer. 2019 Jun;132:160. doi: 10.1016/j.lungcan.2019.04.012. Epub 2019 Apr 24. Lung Cancer. 2019. PMID: 31029398 Free article. No abstract available.
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Kusumoto S, et al. Among authors: kuriki h. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19. Blood. 2019. PMID: 30341058 Free PMC article. Clinical Trial.
90 results